MarketCap
Facebook
X
Telegram
Akebia Therapeutics Revenue | AKBA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Akebia Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 236 M | 160 M | 195 M | 292 M | 212 M | 295 M | 335 M | 208 M | 178 M | 1.54 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 335 M | 1.54 M | 211 M |
Quarterly Revenue Akebia Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 49.1 M | 53.5 M | 58.8 M | 62.5 M | 57.3 M | - | 37.4 M | 43.6 M | 32.6 M | - | 42 M | 56.4 M | 40.1 M | - | 48.7 M | 126 M | 61.7 M | - | 48.8 M | 52.9 M | 52.3 M | - | 60 M | 90.1 M | 88.5 M | - | 92 M | 101 M | 72.7 M | - | 53.2 M | 48.8 M | 45.9 M | - | 41.3 M | 28.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 126 M | 28.5 M | 58.8 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Ionis Pharmaceuticals
IONS
|
203 M | $ 43.5 | 0.62 % | $ 6.96 B |  USA |
 |
Agios Pharmaceuticals
AGIO
|
54 M | $ 31.25 | 0.88 % | $ 1.81 B | USA |
 |
Foghorn Therapeutics
FHTX
|
30.9 M | $ 2.0 | 0.74 % | $ 126 M | USA |
 |
Inhibikase Therapeutics
IKT
|
261 K | $ 2.0 | 0.5 % | $ 197 M | USA |
 |
Kamada Ltd.
KMDA
|
180 M | $ 8.0 | 1.34 % | $ 461 M |  Israel |
 |
Intellia Therapeutics
NTLA
|
67.7 M | $ 12.75 | 4.0 % | $ 1.38 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
673 M | $ 14.5 | 3.19 % | $ 1.43 B | USA |
 |
Viridian Therapeutics
VRDN
|
70.8 M | $ 19.0 | 2.16 % | $ 1.93 B | USA |
 |
AbbVie
ABBV
|
16.6 B | $ 265.76 | 1.12 % | $ 470 B | USA |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 13.78 | 0.29 % | $ 4.12 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
5.82 M | $ 5.11 | 1.59 % | $ 271 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
14.1 M | $ 4.67 | 4.94 % | $ 895 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
1.07 B | $ 20.11 | 0.8 % | $ 3.39 B | USA |
 |
Achieve Life Sciences
ACHV
|
5.06 M | $ 7.01 | 0.13 % | $ 306 M | USA |
 |
AC Immune SA
ACIU
|
3.57 M | $ 2.71 | 0.55 % | $ 273 M |  Schweiz |
 |
Aclaris Therapeutics
ACRS
|
7.83 M | $ 4.27 | 0.79 % | $ 523 M | USA |
 |
Adagene
ADAG
|
7.67 M | $ 2.8 | 0.28 % | $ 165 M |  China |
 |
ADC Therapeutics SA
ADCT
|
81.4 M | $ 1.23 | 8.85 % | $ 156 M | Schweiz |
 |
ADMA Biologics
ADMA
|
510 M | $ 10.11 | 4.01 % | $ 2.41 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
277 M | $ 29.84 | 5.26 % | $ 4.53 B | USA |
 |
Agenus
AGEN
|
114 M | $ 8.73 | 4.43 % | $ 260 M | USA |
 |
AIM ImmunoTech
AIM
|
88 K | $ 0.19 | 5.56 % | $ 308 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
368 K | $ 8.76 | 0.46 % | $ 590 B |  Britain |
 |
Alector
ALEC
|
21 M | $ 1.99 | 9.94 % | $ 205 M | USA |
 |
Aligos Therapeutics
ALGS
|
2.19 M | $ 5.4 | 0.36 % | $ 53.4 M | USA |
 |
Alkermes plc
ALKS
|
1.48 B | $ 42.76 | 2.42 % | $ 7.04 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
22 K | $ 1.5 | 0.33 % | $ 331 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
3.71 B | $ 219.89 | 0.08 % | $ 28.8 B | USA |
 |
Altimmune
ALT
|
41 K | $ 2.67 | 0.36 % | $ 235 M | USA |
 |
ALX Oncology Holdings
ALXO
|
1.18 M | $ 1.21 | 1.23 % | $ 64.9 M | USA |
 |
Amgen
AMGN
|
36.8 B | $ 402.98 | 0.08 % | $ 217 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 25.37 | 0.39 % | $ 1.19 B | USA |
 |
Amarin Corporation plc
AMRN
|
214 M | $ 12.09 | 0.31 % | $ 5.02 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
3.02 B | $ 20.35 | 0.25 % | $ 6.38 B | USA |
 |
AnaptysBio
ANAB
|
53 M | $ 49.2 | 1.38 % | $ 1.43 B | USA |
 |
Anika Therapeutics
ANIK
|
113 M | $ 19.73 | 3.3 % | $ 283 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
883 M | $ 72.58 | 0.55 % | $ 1.46 B | USA |
 |
Aptevo Therapeutics
APVO
|
3.11 M | $ 1.8 | 2.27 % | $ 568 K | USA |
 |
Aquestive Therapeutics
AQST
|
44.5 M | $ 4.57 | 0.44 % | $ 489 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
82 M | $ 14.66 | 12.51 % | $ 401 M | Israel |
 |
Ardelyx
ARDX
|
407 M | $ 3.39 | 1.5 % | $ 817 M | USA |
 |
argenx SE
ARGX
|
36.4 M | $ 912.87 | 1.28 % | $ 56 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
823 K | $ 3.66 | 3.98 % | $ 133 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
376 M | $ 25.15 | 0.04 % | $ 3.2 B | USA |